News
HanchorBio Announces Acceptance of Four Scientific Abstracts for ESMO Congress 2026, Highlighting Differentiated Immunotherapy Strategy
HanchorBio announced that four scientific abstracts covering HCB101 and HCB301 were accepted for ESMO Congress 2026, taking place October 23–27 in Madrid, Spain.
Oct 27, 2026
Read more
HanchorBio Advances HCB101 Global Partnering Opportunities at BIO-Europe 2026
HanchorBio announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany.
Oct 27, 2026
Read more
HanchorBio Advances HCB101 Toward Global Registrational Development Following SAB Review and FDA Alignment
HanchorBio announced outcomes from its latest Scientific Advisory Board (SAB) meeting. Highlights included significant clinical progress for its lead asset, HCB101; alignment with the U.S. FDA on a registrational pathway in second-line gastric/ gastroesophageal junction (GC/GEJ) cancer; and continued expansion of the company’s research pipeline across oncology and immune-mediated diseases.
Oct 19, 2026
Read more
HanchorBio Expands Global Pharma Engagement at BioJapan 2026
HanchorBio announced its participation in BioJapan 2026 in Yokohama, Japan. The Company has scheduled more than 15 partnering meetings with regional and global pharmaceutical leaders to explore co-development and strategic collaboration opportunities across its proprietary Fc-based Designer Biologics (FBDB™) platform.
Oct 12, 2026
Read more
HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day
HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.
Sep 23, 2026
Read more
HanchorBio to Present Five Clinical Abstracts at CSCO 2026
HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).
Sep 18, 2026
Read more
HanchorBio Advances Its Myeloid Enhancer Platform at BioCon China Expo 2026
HanchorBio announced that Founder and Chairman Dr. Scott Liu will present at BioCon China Expo 2026 on September 15.
Sep 14, 2026
Read more
HanchorBio Highlights Clinical, Pipeline, and Global Growth Strategy
HanchorBio highlighted its clinical development, pipeline expansion, and global growth strategy following a presentation at the “2026 Q3 Global Outlook Autumn Investment Forum” hosted by President Securities at Grand Hyatt Taipei.
Sep 08, 2026
Read more
HanchorBio Earns Dual KSMO/FACO 2026 Recognition for HCB101 and HCB301
HanchorBio announced clinical results from HCB101 and HCB301 presented at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), in Seoul, South Korea.
Sep 07, 2026
Read more
HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference
HanchorBio announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20–21, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.
Sep 01, 2026
Read more